RiboPro was awarded a €20,000 MIT grant by the province of Gelderland to investigate the feasibility and business merits of mRNA-delivery vehicle combinations.
RiboPro provides academic and industrial parties with high-quality messenger RNA for research and development. For most applications, the messenger RNA requires a delivery vehicle to reach optimal activity in the cell. Commercial delivery solutions that can be combined with the separately purchased messenger RNA exist, but determining the optimal mRNA-delivery combination then become a responsibility of and a burden for the customer.
To lower the barrier of customers to use messenger RNA, RiboPro will investigate the feasibility of combining in-house the ordered messenger RNA with a delivery vehicle and shipping a completely characterized product to the client.
The benefits would include a lower barrier to entry for novice mRNA users, a higher level of standardization, better comparability to alternative approaches, lower overall costs, and a shorter time to results and publication.
Thus far, there is to our knowledge no party that delivers both high-quality, sequence-optimized (optional) messenger RNA and delivery vehicles, and it is RiboPro’s ambition to be the first to deliver this fully integrated service.
This feasibility study investigates the IP, commercial and scientific challenges to develop and launch this new product and service.
Stay tuned for updates.